Propanc Biopharma, Inc.
PPCB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $16 | $0 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $2 | $1 | $1 | $1 |
| Enterprise Value | $18 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$58 | -$1 | -$2 | -$2 |
| % Margin | – | – | – | – |
| Net Income | -$59 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -14.85 | -1,200 | -31,268.39 | -1,119,475.67 |
| % Growth | 98.8% | 96.2% | 97.2% | – |
| Operating Cash Flow | -$0 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$1 | -$1 | -$1 |